Terms: = Lymphoma AND ERBB3, c-erbB3, 2065, P21860, p180-ErbB3, c-erbB-3, ErbB-3, MDA-BF-1, HER3, p85-sErbB3, MGC88033, p45-sErbB3, ENSG00000065361, erbB3-S
34 results:
1. Systematic characterization of antibody-drug conjugate targets in central nervous system tumors.
Coy S; Lee JS; Chan SJ; Woo T; Jones J; Alexandrescu S; Wen PY; Sorger PK; Ligon KL; Santagata S
Neuro Oncol; 2024 Mar; 26(3):458-472. PubMed ID: 37870091
[TBL] [Abstract] [Full Text] [Related]
2. Role of human epidermal growth factor receptor 3 in treatment resistance of anaplastic lymphoma kinase translocated non-small cell lung cancer.
Honkanen TJ; Luukkainen MEK; Koivunen JP
Cancer Biol Ther; 2023 Dec; 24(1):2256906. PubMed ID: 37722715
[TBL] [Abstract] [Full Text] [Related]
3. Pan-HER inhibitors overcome lorlatinib resistance caused by NRG1/her3 activation in ALK-rearranged lung cancer.
Taniguchi H; Akagi K; Dotsu Y; Yamada T; Ono S; Imamura E; Gyotoku H; Takemoto S; Yamaguchi H; Sen T; Yano S; Mukae H
Cancer Sci; 2023 Jan; 114(1):164-173. PubMed ID: 36086904
[TBL] [Abstract] [Full Text] [Related]
4. Fibroblast growth factor receptor 3 overexpression mediates ALK inhibitor resistance in ALK-rearranged non-small cell lung cancer.
Sakashita T; Yanagitani N; Koike S; Low SK; Takagi S; Baba S; Takeuchi K; Nishio M; Fujita N; Katayama R
Cancer Sci; 2022 Nov; 113(11):3888-3900. PubMed ID: 35950895
[TBL] [Abstract] [Full Text] [Related]
5. GZ17-6.02 and palbociclib interact to kill ER+ breast cancer cells.
Booth L; West C; Moore RP; Von Hoff D; Dent P
Oncotarget; 2022; 13():92-104. PubMed ID: 35035775
[TBL] [Abstract] [Full Text] [Related]
6. Integrative genomic and transcriptomic analysis in plasmablastic lymphoma identifies disruption of key regulatory pathways.
Witte HM; Künstner A; Hertel N; Bernd HW; Bernard V; Stölting S; Merz H; von Bubnoff N; Busch H; Feller AC; Gebauer N
Blood Adv; 2022 Jan; 6(2):637-651. PubMed ID: 34714908
[TBL] [Abstract] [Full Text] [Related]
7. The Oncogenic Signaling Disruptor, NDRG1: Molecular and Cellular Mechanisms of Activity.
Chekmarev J; Azad MG; Richardson DR
Cells; 2021 Sep; 10(9):. PubMed ID: 34572031
[TBL] [Abstract] [Full Text] [Related]
8. Whole-exome mutational landscape of neuroendocrine carcinomas of the gallbladder.
Liu F; Li Y; Ying D; Qiu S; He Y; Li M; Liu Y; Zhang Y; Zhu Q; Hu Y; Liu L; Li G; Pan W; Jin W; Mu J; Cao Y; Liu Y
Signal Transduct Target Ther; 2021 Feb; 6(1):55. PubMed ID: 33563892
[TBL] [Abstract] [Full Text] [Related]
9. Association of Combined Modality Therapy vs Chemotherapy Alone With Overall Survival in Early-Stage Pediatric Hodgkin lymphoma.
Jhawar SR; Rivera-Núñez Z; Drachtman R; Cole PD; Hoppe BS; Parikh RR
JAMA Oncol; 2019 May; 5(5):689-695. PubMed ID: 30605220
[TBL] [Abstract] [Full Text] [Related]
10. R-High-CHOP/CHASER/LEED with autologous stem cell transplantation in newly diagnosed mantle cell lymphoma: JCOG0406 STUDY.
Ogura M; Yamamoto K; Morishima Y; Wakabayashi M; Tobinai K; Ando K; Uike N; Kurosawa M; Gomyo H; Taniwaki M; Nosaka K; Tsukamoto N; Shimoyama T; Fukuhara N; Yakushijin Y; Ohnishi K; Miyazaki K; Sawada K; Takayama N; Hanamura I; Nagai H; Kobayashi H; Usuki K; Kobayashi N; Ohyashiki K; Utsumi T; Kumagai K; Maruyama D; Ohmachi K; Matsuno Y; Nakamura S; Hotta T; Tsukasaki K;
Cancer Sci; 2018 Sep; 109(9):2830-2840. PubMed ID: 29957865
[TBL] [Abstract] [Full Text] [Related]
11. HER2 regulates cancer stem-like cell phenotype in ALK translocated NSCLC.
Honkanen T; Wilenius E; Koivunen P; Koivunen JP
Int J Oncol; 2017 Aug; 51(2):599-606. PubMed ID: 28656214
[TBL] [Abstract] [Full Text] [Related]
12. erbb3: A potential serum biomarker for early detection and therapeutic target for devil facial tumour 1 (DFT1).
Hayes DA; Kunde DA; Taylor RL; Pyecroft SB; Sohal SS; Snow ET
PLoS One; 2017; 12(6):e0177919. PubMed ID: 28591206
[TBL] [Abstract] [Full Text] [Related]
13. Incidence and epidemiology of non-Hodgkin lymphoma and risk of second malignancy among 22 466 survivors in Israel with 30 years of follow-up.
Tadmor T; Liphshitz I; Silverman B; Polliack A
Hematol Oncol; 2017 Dec; 35(4):599-607. PubMed ID: 27238496
[TBL] [Abstract] [Full Text] [Related]
14. Elucidation of Resistance Mechanisms to Second-Generation ALK Inhibitors Alectinib and Ceritinib in Non-Small Cell Lung Cancer Cells.
Dong X; Fernandez-Salas E; Li E; Wang S
Neoplasia; 2016 Mar; 18(3):162-71. PubMed ID: 26992917
[TBL] [Abstract] [Full Text] [Related]
15. Non-Small Cell Lung Cancer Cells Acquire Resistance to the ALK Inhibitor Alectinib by Activating Alternative Receptor Tyrosine Kinases.
Isozaki H; Ichihara E; Takigawa N; Ohashi K; Ochi N; Yasugi M; Ninomiya T; Yamane H; Hotta K; Sakai K; Matsumoto K; Hosokawa S; Bessho A; Sendo T; Tanimoto M; Kiura K
Cancer Res; 2016 Mar; 76(6):1506-16. PubMed ID: 26719536
[TBL] [Abstract] [Full Text] [Related]
16. Ibrutinib (ImbruvicaTM) potently inhibits ErbB receptor phosphorylation and cell viability of ErbB2-positive breast cancer cells.
Grabinski N; Ewald F
Invest New Drugs; 2014 Dec; 32(6):1096-104. PubMed ID: 25081321
[TBL] [Abstract] [Full Text] [Related]
17. Α-eleostearic acid inhibits growth and induces apoptosis in breast cancer cells via HER2/her3 signaling.
Zhuo RJ; Wang F; Zhang XH; Zhang JJ; Xu J; Dong W; Zou ZQ
Mol Med Rep; 2014 Mar; 9(3):993-8. PubMed ID: 24425042
[TBL] [Abstract] [Full Text] [Related]
18. Patients with primary diffuse large B-cell lymphoma of female genital tract have high risk of central nervous system relapse.
Cao XX; Li J; Zhang W; Duan MH; Shen T; Zhou DB
Ann Hematol; 2014 Jun; 93(6):1001-5. PubMed ID: 24408160
[TBL] [Abstract] [Full Text] [Related]
19. High-dose methotrexate, high-dose cytarabine and temozolomide for the treatment of primary central nervous system lymphoma (PCNSL).
Salamoon M; Hussein T; Kenj M; Bachour M
Med Oncol; 2013 Dec; 30(4):690. PubMed ID: 23959450
[TBL] [Abstract] [Full Text] [Related]
20. Activation of HER family signaling as a mechanism of acquired resistance to ALK inhibitors in EML4-ALK-positive non-small cell lung cancer.
Tanizaki J; Okamoto I; Okabe T; Sakai K; Tanaka K; Hayashi H; Kaneda H; Takezawa K; Kuwata K; Yamaguchi H; Hatashita E; Nishio K; Nakagawa K
Clin Cancer Res; 2012 Nov; 18(22):6219-26. PubMed ID: 22843788
[TBL] [Abstract] [Full Text] [Related]
[Next]
